EnWave Appoints New Executive Chairman, Announces Change in Management, Private Placement with Director and Grants Stock Opti...
23 Giugno 2014 - 3:00PM
Marketwired
EnWave Appoints New Executive Chairman, Announces Change in
Management, Private Placement with Director and Grants Stock
Options
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 23, 2014) -
EnWave Corporation (TSX-VENTURE:ENW)(FRANKFURT:E4U) ("EnWave", or
the "Company") is pleased to announce the appointment of Mr. John
P.A. Budreski as a Director and Executive Chairman of the Board of
EnWave.
Mr. Budreski joins EnWave with over 30 years of extensive
capital markets and executive management experience. Mr. Budreski
has a professional history of advancing and accelerating
businesses, as well as tangible engineering experience. He was
formerly a Vice Chairman of Cormark Securities Inc. from 2009 to
2012 and President and CEO of Orion Securities Inc. from 2005 to
2007, prior to its successful sale to Macquarie Bank. He has filled
the roles of a Managing Director of Equity Capital Markets and Head
of Investment Banking for Scotia Capital Inc. from March 1998 to
February 2005 after starting out as a Managing Director of US
Institutional Equity Group for Scotia Capital. He also held senior
roles in investment banking and equity sales and trading for RBC
Dominion Securities. Mr. Budreski is currently a Director of
Sandstorm Gold Ltd., Alaris Royalty Corporation and Delta Gold
Corporation. He is also the Chief Executive Officer and a Director
of Morien Resources Corporation. He holds a Bachelor of Engineering
from Dalhousie / TUNS University and an MBA from the University of
Calgary.
With Mr. Budreski's appointment, Dr. Tim Durance will become the
sole President and Chief Executive Officer of the Company and
vacate the position of Chairman on the Board of Directors. The
Company also announces that, effective June 30th, 2014, Mr. John
McNicol, who served as the Company's President, co-CEO and as a
Director on the Board from February 2007 until June 2014, will be
reducing his role with EnWave to become a Consultant, enabling him
to pursue personal interests.
"EnWave's management is very pleased to have such a qualified
business professional join the executive team, especially at a time
when the Company's Radiant Energy Vacuum ("REV™") technology is
experiencing a commercialization inflection point," stated Dr. Tim
Durance, President & CEO of EnWave. "On behalf of the EnWave
Board and management team I would also like to thank John McNicol
for his valued contributions to the development of EnWave over the
past seven years."
Additionally, EnWave announces that it has granted a total of
800,000 stock options to Mr. Budreski pursuant to its Share Option
Plan (the "Plan"). Each option will entitle Mr. Budreski to
purchase one common share of the Company at an exercise price of
$1.35 per share for a period of five years from this date. The
options will vest in accordance to provisions set out in the Plan,
or as otherwise required by the TSX Venture Exchange. The grant is
subject to regulatory approval.
The stock options granted to Mr. Budreski are part of his
compensation package and will provide him with an opportunity to
establish a meaningful position in EnWave as the Company continues
to progress.
Lastly, the Company announces that it has agreed to a private
placement (the "Private Placement") with Mr. Budreski, who will be
adding to his existing holdings of EnWave through the purchase of
111,111 common shares at price of $1.35 per share, for cash
proceeds to the Company of $150,000.
The net proceeds from the Private Placement shall be used for
working capital and general corporate purposes.
The common shares of Enwave to be issued in connection with the
Private Placement will be subject to a statutory four-month hold
period. Completion of the Private Placement is subject to a number
of conditions, including, without limitation, the receipt of all
required regulatory approvals, including approval of the TSX
Venture Exchange.
About EnWave
EnWave Corporation is a Vancouver-based industrial technology
company developing commercial applications for its proprietary
Radiant Energy Vacuum (REV™) dehydration technology. EnWave aims to
sign royalty-bearing commercial licenses with leading food and
pharmaceutical companies for the use of its revolutionary
technology. Thus far the Company has signed ten royalty-bearing
licenses, opening up eight distinct market sectors for
commercialization with companies that include Bonduelle, a global
leader in the production of vegetables; Hormel Foods Corporation, a
major processed meat manufacturer in the United States of America;
and Sutro Biopharma, a company developing a protein synthesis
process for the pharmaceutical industry. In addition to these
licenses, EnWave has formed a Limited Liability Partnership,
NutraDried LLP, to develop, manufacture, market and sell
all-natural cheese snack products in the United States under the
Moon Cheese® brand. The Company has also signed a license and
manufacturing agreement with NutraDried Creations to market the
dried cheese and other REV™ snack products through private label
distribution channels in the United States and Latin America.
EnWave has signed a wide range of research agreements with an
expanding list of companies that include Nestlé, Kellogg's, Ocean
Spray Cranberries, Sun-Maid Growers, R.J. Reynolds and Merck among
others. EnWave is introducing REV™ as a new dehydration standard in
the food and biological material sectors: potentially faster and
cheaper than freeze drying, with better end product quality than
air drying or spray drying.
EnWave currently has six REV™ platforms: commercial-scale
nutraREV® and MIVAP® are used in the food industry to dry
food products quickly and at low-cost, while maintaining high
levels of nutrition, taste, texture and colour. The Company has
also commercialized powderREV® for bulk dehydration of
food cultures, probiotics and fine biochemicals such as enzymes
below the freezing point; quantaREV™ for continuous,
high-volume low-temperature drying; and bioREV™ and
freezeREV™ as new methods to stabilize and dehydrate
biopharmaceuticals such as vaccines and antibodies. More
information about EnWave is available at www.enwave.net.
EnWave Corporation |
Dr. Tim Durance |
President, CEO & Director |
Safe Harbour for Forward-Looking Information Statements:
This press release may contain forward-looking information based on
management's expectations, estimates and projections. All
statements that address expectations or projections about the
future, including statements about the Company's strategy for
growth, product development, market position, expected
expenditures, and the Private Placement are forward-looking
statements. These statements are not a guarantee of future
performance and involve a number of risks, uncertainties and
assumptions. Although the Company has attempted to identify
important factors that could cause actual results to differ
materially, there may be other factors that cause results not to be
as anticipated, estimated or intended. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Mr. John BudreskiExecutive ChairmanEnWave Corporation(+1)
416-930-0914E-mail: jbudreski@enwave.netMr. Brent CharletonVice
President, Corporate Affairs(+1) 778-378-9616E-mail:
bcharleton@enwave.net
Grafico Azioni EnWave (TSXV:ENW)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni EnWave (TSXV:ENW)
Storico
Da Gen 2024 a Gen 2025